Fondaparinux Subcutaneous and Moxetumomab pasudotox
Determining the interaction of Fondaparinux Subcutaneous and Moxetumomab pasudotox and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: fondaparinux
Brand name: Arixtra, Arixtra 5 mg/dose, Arixtra 75 mg/dose, Arixtra 10 mg/dose
Synonyms: Fondaparinux
Generic Name: moxetumomab pasudotox
Brand name: Lumoxiti
Synonyms: Moxetumomab Pasudotox
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fondaparinux Subcutaneous-Moxetumomab Pasudotox-tdfk
- Fondaparinux Subcutaneous-Moxetumomab pasudotox-tdfk Intravenous
- Fondaparinux Subcutaneous-Moxifloxacin
- Fondaparinux Subcutaneous-Moxifloxacin (Systemic)
- Fondaparinux Subcutaneous-Moxifloxacin Hydrochloride
- Fondaparinux Subcutaneous-Moxifloxacin Injection
- Moxetumomab pasudotox-Foradil
- Moxetumomab pasudotox-Foradil Aerolizer
- Moxetumomab pasudotox-Forane
- Moxetumomab pasudotox-Forfivo XL
- Moxetumomab pasudotox-Formerly available as Dalmane
- Moxetumomab pasudotox-Formerly available as Librium